GlassScriptPhysician profile
Elizabeth Allen
NPI 1356380489
$2,040.03
in general payments reported to CMS, 2019-2025
22 companies · $501 in 2025
The $501 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $284 · 2021: $74.33 · 2022: $125 · 2023: $13.16 · 2024: $201 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424 · Consulting Fee: $175 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.53 |
| Consulting Fee | $175.00 |
| Education | $116.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $250.95 | 2019-2020 | |
| Amgen INC. | $207.62 | 2019-2025 | Prolia |
| Abbvie INC. | $193.48 | 2019-2020 | |
| Pfizer INC. | $166.32 | 2019-2020 | |
| Novo Nordisk INC | $153.16 | 2022-2024 | Wegovy |
| Amag Pharmaceuticals, INC. | $151.71 | 2019-2020 | |
| Millicent US INC | $116.70 | 2024-2025 | |
| Lilly USA, LLC | $110.42 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Therapeuticsmd, INC. | $101.32 | 2019 | |
| Allergan, INC. | $92.78 | 2019-2020 | |
| Axsome Therapeutics, INC. | $92.27 | 2025 | Symbravo, Auvelity |
| Hologic Sales and Service, LLC | $80.37 | 2024-2025 | Aptima |
| Philips North America LLC | $74.33 | 2021 | |
| Lupin INC. | $63.81 | 2019 | |
| Merck Sharp & Dohme LLC | $39.32 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $32.22 | 2024 | Paragard T 380a |
| Astellas Pharma US INC | $23.12 | 2025 | Veozah |
| Dexcom, INC. | $20.35 | 2025 | Dexcom G6 Transmitter |
| Mylan Pharmaceuticals INC. | $19.79 | 2020 | |
| Organon LLC | $18.66 | 2025 | Jada System |
| Otsuka America Pharmaceutical, INC. | $17.95 | 2024 | Rexulti |
| Vertical Pharmaceuticals, LLC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.